Angel investors are invaluable for bridging the ‘valley of death’ between seed corn funding and institutional investment. Having discovered that a good number of angels are based in Norfolk, the Norwich Research Park has created an initiative called Venta to help showcase some of the exciting research that is emerging from the university and research institutes based on the park.
The first meeting was very successful and the next meeting coming up on the 26th April is spreading the net wider and encouraging entrepreneurs, scientists and technologists from further a field to apply for pitching and elevator slots.
A good number of exciting companies have been attracted to the facilities on the Norwich Research Park, which already includes an innovation centre and bio-incubator with plans for a next-generation science and innovation park.
Norfolk is well renowned for the quality of its food and also for its research in this area.
Richard Mithen, from the Institute of Food Research (IFR), made the headlines recently with Beneforté broccoli which went on sale in October. Using conventional breeding techniques, he was able to increase the levels of glucoraphanin, a naturally occurring beneficial chemical that is thought to help lower rates of heart disease and some forms of cancer.
New approaches to pharmacology is another area of research that is translating into business opportunities.
A recent John Innes spinout is Procarta, established by John Innes Centre (JIC) scientist Dr Michael McArthur based on his ‘snare’ technology. This is a new type of antibiotic that can help the fight against drug-resistant infections. Snare kills bacteria by blocking the action of some of its essential genes. The company is focussing on ‘super bugs’ such as MRSA and E. coli but its scope is impressive and promises a real alternative to traditional antibiotics.
Jonathan Clarke JIC Business Development says that a new generation of industry is emerging and the centre has many technologies in the pipeline:
“Many of the newer drugs developed for the treatment of cancer and other conditions are protein based and are expensive to produce. If we can use plants to produce the right sorts of protein we can literally grow new treatments and vaccines.”
JIC has a new technology called Transferon which can create high-value proteins in plants. Vaccines, such as those for flu, work by exposing the body to a small amount of attenuated virus to stimulate the natural defence process. It is now possible to do this in a plant and JIC has successfully created vaccines using tobacco plants. Vaccines are heat sensitive and traditionally difficult to transport. This technology creates the possibility for vaccines to be grown near to people that are affected by the disease.
The location of the Norfolk and Norwich University Hospital on the Norwich Research Park creates opportunities for scientists to interact with clinicians. The hospital is involved in a number of wide scale, clinical trials that benefit for the stable population in the region.
Norwich Research Park is set to play an important role in the innovation economy of the UK, with the continuing expansion over the next 5 years of its next generation research and innovation park.
Those interested in participating in Venta either as a potential investor with an interest in science-based technologies or as an entrepreneur then please contact John Irving venta@nrpic.com.








